Unusually large extraintestinal GIST presenting as an abdomino-pelvic tumor

Matteo, Diana; Dandolu, Vani; Lembert, Larissa; Thomas, Rebecca; Chatwani, Ashwin

doi:10.1007/s00404-007-0528-9

Cited by 13 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumors may appear as well-defined or polylobulated firm mass with or without cystic, necrotic degeneration. They range in size from 2.1 to 32 cm with most of the tumor more than 5 cm in size as they have enough space to grow and are usually inseparable from the wall of the stomach or intestine [1, 7, 8]. EGISTs usually affect females whose ages range from 31 to 82 years (mean, 58 years).…”

Section: Discussionmentioning

confidence: 99%

“…95% of GISTs are found with CD117 somatic mutation. CD117 is a tyrosine kinase transmembrane receptor located on chromosome 4 which is also the product of proto-oncogene c-kit [1]. …”

Section: Discussionmentioning

confidence: 99%

“…Gastrointestinal stromal tumors are rare visceral neoplasms that arise from gastrointestinal tract and most often express immunoreactivity for CD-117, a c-kit proto-oncogene protein [1]. The clinicopathological and immunohistochemical features of CD-117 positive mesenchymal tumors without connection to the gastrointestinal tract, are known as extragastrointestinal stromal tumors [2].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Extragastrointestinal Stromal Tumor during Pregnacy

Gözükara

Dilek

Durukan

et al. 2012

Case Reports in Obstetrics and Gynecology

View full text Add to dashboard Cite

Extragastrointestinal stromal tumors (EGISTs) are mesenchymal neoplasms without connection to the gastrointestinal tract. Gastrointestinal stromal tumors (GISTs) and EGIST are similar according to their clinicopathologic and histomorphologic features. Both of them most often express immunoreactivity for CD-117, a c-kit proto-oncogene protein. The coexistence of GIST and pregnancy is very rare, with only two cases reported in the literature. In this paper, we presented the first EGIST case during pregnancy in the literature.

show abstract

Section: Discussionmentioning

confidence: 99%

“…95% of GISTs are found with CD117 somatic mutation. CD117 is a tyrosine kinase transmembrane receptor located on chromosome 4 which is also the product of proto-oncogene c-kit [1]. …”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Extragastrointestinal Stromal Tumor during Pregnacy

Gözükara

Dilek

Durukan

et al. 2012

Case Reports in Obstetrics and Gynecology

View full text Add to dashboard Cite

show abstract

“…Tumors may appear as well-defined or polylobulated firm masses with or without cysts, necrosis, or degeneration. They range in size from 2.1 to 32 cm and most are more than 5 cm, because of the space available for growth, and are usually inseparable from the wall of the stomach or intestine, 6 but the tumor of this patient was easily separated from the wall of stomach. Abdominal ultrasonography is the first-line screening modality used to detect the presence of a mass and to differentiate cystic and solid tumors.…”

Section: Discussionmentioning

confidence: 99%

Extragastrointestinal Stromal Tumor Mimicking Gastric Subepithelial Tumor

Kim

2014

J Minim Invasive Surg

View full text Add to dashboard Cite

Gastrointestinal strom al tum or (GIST) is the m ost com m on m esenchym al tum or of the gastrointestinal tract; how ever, it also occurs at a low er frequency in extra-gastrointestinal regions, such as om entum , m esentery, retroperitoneum , and undefined abdom inal sites. This tum or is called an extragastrointestinal strom al tum or (EG IST). A 53-year-old w om an presented w ith a gastric subepithelial tum or, w hich w as incidentally detected by gastrofiberscopy. Contrast abdom inal com puted tom ography (CT) show ed a w ell-defined exophytic tum or w ith a m inim ally delayed peripheral enhancing nature near the gastrohepatic ligam ent. Surgical intervention w as indicated, and laparoscopic surgery w as planned. D uring surgery, no specific abnorm ality w as found in the gastric w all and there w as no evidence of a gastric subepithelial tum or. Based on im m unohistochem ical results, sensitive and specific im m unostaining w as observed for c-KIT, DO G-1, and PKC-θ. In this case, the tum or w as positive for CD -117(c-kit) and for sm ooth m uscle actin expression.

show abstract

“…The prognosis of patients with a GIST is based on tumor size, mitotic rate, and organ of origin. The published literature on GISTs in patients who present with an abdominal or pelvic mass is limited to isolated case reports and single case series [5][6][7][8][9][10][11][12][13]. The goal of this retrospective study was to report on a series of patients who presented with a presumptive diagnosis of ovarian cancer in gynaecologic oncology department and all were finally diagnosed to have a GIST.…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal Stromal Tumor Mimicking as Ovarian Tumor in Gynaecologic Oncology

Ijeri

Rathod

Kundargi

et al. 2015

Indian J Surg Oncol

View full text Add to dashboard Cite

To report the clinical presentation and outcomes of a series of patients who presented with abdominal/pelvic mass or pelvic pain and were diagnosed with a gastrointestinal stromal tumor (GIST). Retrospective data were collected of all patients who presented with an abdominal/pelvic mass or pelvic pain between January 2010 and July 2015 and who were ultimately diagnosed with a GIST. The patients' medical records were reviewed. A literature review was also conducted. The event free survival and overall survival was calculated for all patients using Kaplan Meier curve (SPSS19-SPSS Inc. USA). A total ten patients were identified with GIST during the study period. Eight of ten patients had a tumor in the small intestine, one in sigmoid colon and one in base of small bowel mesentry. The mean tumor size was 13.9 cm (range, 3.9 to 24 cm). A complete resection was achieved in all 10 patients. No patient had distance metastasis. There were no intraoperative complications. One patient developed postoperative intestinal fistula and was managed conservatively. All patients were treated with imatinib after surgery. The mean follow-up time was 18 months (range, 2 to 47 months). The seven of the 10 patients (70 %) with no evidence of disease, two (20 %) lost follow up and one patient developed recurrence during follow up period and was started on sunitinib and patient died during follow up period because of disease. Gastrointestinal stromal tumors should be considered in the differential diagnosis of patients presenting with an abdominal/pelvic mass or pelvic pain in Gynaecologic oncology department. In such unusual circumstances the complete resection and appropriate adjuvant treatment results in complete durable remission.

show abstract

Unusually large extraintestinal GIST presenting as an abdomino-pelvic tumor

Abstract: Gynecologists need to be cognizant of extra-ovarian pathology in the atypical presentation of a pelvic mass. Correct diagnosis is essential for proper management since GISTs specifically respond to the c-kit selective tyrosine kinase inhibitor, Imatinib mesylate.

Cited by 13 publications

References 13 publications

Extragastrointestinal Stromal Tumor during Pregnacy

Extragastrointestinal Stromal Tumor during Pregnacy

Extragastrointestinal Stromal Tumor Mimicking Gastric Subepithelial Tumor

Gastrointestinal Stromal Tumor Mimicking as Ovarian Tumor in Gynaecologic Oncology

Contact Info

Product

Resources

About